不同剂量米非司酮治疗围绝经期子宫小肌瘤临床效果及对血管内皮生长因子和其受体表达的影响  

Effects of different doses of mifepristone on the clinical efficacy and expression of vascular endothelial growth factor and its receptor in patients with uterine leiomyoma in perimenopausal period

作　　者：沈丹 

机构地区：[1]上海新华医院崇明分院妇产科,上海202150

出　　处：《临床检验杂志（电子版）》2016年第2期81-83,共3页Clinical Laboratory Journal(Electronic Edition)

摘　　要：目的探讨不同剂量米非司酮应用于围绝经期子宫小肌瘤患者的临床治疗效果及对血管内皮生长因子和受体表达的影响。方法选取2014年8月-2015年4月间我院收治的82例围绝经期子宫小肌瘤患者,随机分为研究组和对照组,每组各41例。研究组患者每日给予12.5 mg米非司酮口服,对照组患者每日给予25.0 mg米非司酮口服。比较两组患者治疗的临床疗效及治疗前后血管内皮生长因子(vascular endothelial growth factor,VEGF)及其受体VEGFR1、VEGFR2表达的情况。结果经过治疗后,研究组和对照组患者子宫肌瘤体积均较之前显著减小,治疗总有效率均为100.0%,组间差异无统计学意义(P>0.05);治疗后研究组和对照组患者VEGF、VEGFR1、VEGFR2水平均较之前显著降低,组内差异均有统计学意义(P<0.05),但组间差异无统计学意义(P>0.05)。结论应用小剂量米非司酮即可获得理想围绝经期子宫小肌瘤治疗效果,有效改善VEGF及其受体水平。Objective To investigate the effects of different doses of mifepristone on the clinical effect and expression of vascular endothelial growth factor （VEGF） and its receptor in patients with uterine leiomyoma in perimenopausal period. Methods From August 2014 to April 2015, 82 patients with perimenopausal uterine myoma were selected as the research object. They were randomly divided into study group and control group, with 41 cases in each group. Patients in the study group were treated with 12.5 mg mifepristone orally, while the control group was treated with 25.0 mg mifepristone orally. The clinical efficacy and the changes of VEGF, VEGFR1, and VEGFR2 expression of vascular endothelial growth factor before and after treatment were compared between the two groups. Results After treatment, the uterine fibroids volume of the patients in the study group and the control group was significantly reduced than before, and the total effective rate was 100.0%. There was no significant difference between the two groups （P〉0.05）. The levels of VEGF, VEGFR1 and VEGFR2 in the study group and the control group after treatment were significantly lower than before treatment, and the difference was statistically significant （P〈0.05）. But there was no significant difference between the two groups （P〉0.05）. Conclusion The ideal therapeutic effect can be obtained by using low dose mifepristone and effectively improved the level of vascular endothelial growth factor and its receptor in patients with uterine leiomyoma in perimenopausal period.

关 键 词：子宫小肌瘤 围绝经期 米非司酮 临床疗效 血管内皮生长因子 受体 

分 类 号：R737.33[医药卫生—肿瘤]